Lv21
110 积分 2026-02-05 加入
Pharmacovigilance study and development of a clinical decision flowchart for personalized selection of trastuzumab, T-DXd, and T-DM1 in breast cancer patients
1小时前
已完结
Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02
1小时前
已关闭
T-DXd is effective after T-DM1
1小时前
求助中
Abstract PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03)
1小时前
已关闭
CO185 Preliminary Real-World Comparative Analysis of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in Second-Line HER2-Positive Metastatic Breast Cancer
1小时前
求助中
皖公网安备34019202002308
